Stocks and Investing
Stocks and Investing
Thu, November 16, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 15, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ross Osborn Maintained (SMTI) at Buy with Decreased Target to $49 on, Nov 15th, 2023
Ross Osborn of Cantor Fitzgerald, Maintained "Sanara MedTech Inc." (SMTI) at Buy with Decreased Target from $59 to $49 on, Nov 15th, 2023.
Ross has made no other calls on SMTI in the last 4 months.
There is 1 other peer that has a rating on SMTI. Out of the 1 peers that are also analyzing SMTI, 0 agree with Ross's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ross
- Brandon Folkes of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $59 on, Tuesday, September 26th, 2023
Contributing Sources